Evaluating the immunogenicity and safety of the SARS-CoV-2 revombinant vaccine GBP510 (IMAGE)

Korea University College of Medicine

Evaluating the immunogenicity and safety of the SARS-CoV-2 revombinant vaccine GBP510

Caption

The adjuvanted recombinant nanoparticle-based vaccine GBP510/AS03 shows a clinically acceptable safety profile and immunogenicity results comparable to that of the currently available ChAdOx1-S vaccine.

Credit

Cheong et al., Korea University

Usage Restrictions

Cannot be reused without permission

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.